Phenomenex Application Note
This study demonstrates how the ultra-high performance of 1.7 µm core-shell columns can be used in the laboratory in order to realize significant cost savings.
Columns: Kinetex 1.7 µm and 2.6 µm C18, 100 × 2.1 mm
Mobile phase: A: 5 mM Ammonium formate pH 3.25 / Acetonitrile (95:5)
B: 5 mM Ammonium formate pH 3.25 / Acetonitrile (10:90)
Gradient: See Table 1
Flow-rate: 0.4 mL/min
Temperature: 50 °C
Detector: PDA 210-300 nm, extracted channels 225 nm and 280 nm
Instrument: Waters ACQUITY equipped with PDA
Sample:
1. Antidepressant drug (containing a HCl salt); 2. Hormone therapy #1 (containing a salt); 3. SERM drug (containing a basic functional group); 4. CNS drug (containing basic functional group); 5. PPI drug (containing basic functional group); 6. CNS drug (containing basic functional group); 7. CNS drug (containing basic functional group); 8. Hormone therapy #2 (neutral); 9. Oral contraceptive hormone #1 (neutral); 10. Hormone therapy #3 (neutral); 11. Oral contraceptive hormone #2 (neutral); 12. Hormone therapy #4 (neutral); 13. Oral contraceptive hormone (neutral); 14. Hormone therapy #5 (neutral); 15. Hormone therapy #6 (acetate salt of 14); 16. Immunosuppressant drug (macromolecule, containing basic functional group)
Table 1: Gradient.
A swab containing residual API from different production surfaces was extracted with 2 mL of a solution containing a mixture of 1:1 acetonitrile/water and shaken for 5 minutes.
The API's (Active pharmaceutical ingredients) used in these experiments are a mixture of organic salts, organic bases and neutral organic compounds. The analysis was performed on a Phenomenex Kinetex 1.7 µm C18 column under gradient conditions with a flow-rate of 0.4 mL/min. Two different UV wavelengths were used for quantification, 225 nm as shown in Figure 1(a) and 280 nm as shown in Figure 1(b).
Figure 1: Sample chromatogram at (a) 225 nm; and (b) 280 nm, using a Kinetex C18 1.7 µm, 100 à 2.1 mm.
A reduced run time of 6 minutes compared to the 10–20 min in the original method was achieved. The critical pair for separation was compounds 5 and 6, as the closest eluting peaks. However, molecules 5 and 6 are not in the same class of drug and would not routinely be manufactured on the same equipment set and hence seen in the same sample. Therefore complete resolution was not required.
A new analytical method was developed which is capable of analysing 16 different API residues from production surfaces. It has been shown that the 1.7 µm Kinetex 100 × 2.1 mm column was capable of resolving 16 different chemical entities with a 6 minute run time. This new analytical method will be used to replace 16 older methods thereby facilitating an annualised cost saving for the site of €320000.
For complete details request Laboratory Case Study by Andrew Charles et al.
Phenomenex Inc.
411 Madrid Ave., Torrance, California, USA
tel: +1 310 212 055 fax: +1 310 212 7768
Website: www.phenomenex.com
Pharmaceutical excipients, such as polyethylene glycol-based polymers, must be tested for the presence of ethylene oxide (EtO) and 1,4-dioxane as part of a safety assessment, according to USP Chapter <228>.
AOAC International Awarded NIST Grant for Developing Drug Testing Standards
October 31st 2024The grant will be part of a new collaborative scientific initiative to address the need for standards that define the desired performance of lateral flow immunoassay test strips to detect illicit drugs in tablets and powders.